Speakers

Paul Nioi

SVP, Research

Alnylam

Malgorzata Gonciarz

Global Head xRNA Therapeutics

Novartis

Karina Thorn

Corporate Vice President, Head of Research, Global Nucleic Acid Therapies Research

Novo Nordisk

Annette Bak, Ph.D.

Head of Advanced Drug Delivery

AstraZeneca

Tao Pei, PhD

Senior Vice President, Chemistry

Arrowhead Pharmaceuticals

James Powell

VP RNAi CMC, Boulder Site Head

Novo Nordisk

Marc Abrams

CTO & Head of US Operations

SanegeneBio

Sudhir Agrawal

President and Founder

Arnay Sciences

Clay Alspach

Executive Director

Alliance for mRNA Medicines

Gilles Besin, Ph.D.

Chief Scientific Officer

Orbital Therapeutics

Oxana Beskrovnaya, Ph.D.

Senior Vice President, Head of Research

Dyne Therapeutics

Bhawanjit Brar

CEO

Jaan Biotherapeutics

Margaret Brousseau

Executive Director

Novartis

Bao Cai, PhD

Executive Director, Process Development

Sarepta Therapeutics

James Carroll

Managing Director - Life Science Investments

Wharton Alumni Angels

Todd Chappell

COO

Korro Bio

Weijun Chen, PhD

Director, RNA Technologies Lead

Intellia Therapeutics

Wayne Doyle

Head of Platform

Eclipse Bioinnovations

Denis Drygin

SVP R&D

Nosis Biosciences

Satish Eraly

Senior Medical Director

Alnylam Pharmaceuticals

Fred Fleitz

Group Vice President, CMC

Arrowhead Pharmaceuticals

Shanthi Ganesh

Director

Novo Nordisk

Mr Daniel Getts

CEO

Myeloid Therapeutics

Malgorzata Gonciarz

Global Head xRNA Therapeutics

Novartis

Tamar Grossman

CEO

La Jolla Labs

Yacoub Habib

CEO

Ophidion, Inc.

Michelle Hall

Associate VP - Genetic Medicine Research

Eli Lilly & Company

Michael Hodges

CEO

1strand San Diego County RNA cluster

Steve Hughes

CMO

Avidity Biosciences

Travis Hughes

Digitalis Ventures

Digitalis Ventures

David Huss

CSO

Shape Therapeutics

Stuart Hwang

Partner

Remiges Ventures

Randall Hyer

Chief Executive Officer

Merlin Biotech

Nikola Ivica

Head of Discovery

InnDura Therapeutics

Rory Johnson

Associate Professor

University College Dublin

Michael Khan

CEO

ARGONAUTE RNA LIMITED

Garth Kinberger

SVP of Chemistry

Atalanta Therapeutics

Tasuku Kitada

President and Head of R&D

Strand Therapeutics

Tomas Kostelec

Manager of Segment Technology for Advanced Therapies

Sartorius

Mark Lowenthal

Research Chemist

National Institute of Standards and Technology

Dr. Stefan Lutz, Ph.D.

Senior Vice President, Research

Codexis

Dave Madge, PhD

Vice President, Research Services Division

WuXi AppTec

Dinesh Manvar

Associate Director, Analytical Sciences

Sail Bio

Craig Martin

Professor

University of Massachusetts Amherst

Lynda Menard

Advisor

RibroPro

Alison Moore

Chief Technical Officer

Codexis

Christopher O'Donnell

Global Head of Cardiovascular & Metaboli

Novartis

Samir Ounzain

CEO

HAYA Therapeutics

Thaminda Ramanayake

CBO

CureVac

Curtis Rambaran

CMO

Silence Therapeutics

Dmitry Samarsky

Chief Technology Officer

GALCONDA THERAPEUTICS

Dr. Babak Sanii

Director of Biochip R&D

Nutcracker Therapeutics

Philipp Schreppel

Senior Director Business Development

Ethris

Alfica Sehgal, PhD

Chief Scientific Officer

Judo Bio

Mr Attila Seyhan

Director of Translational Oncology Operations at Cancer Center

Brown University

Richard Shen

Co-Founder

EndoTope Bio

Konstantina Skourti-Stathaki

Senior Director, ASO Discovery and Research

n-Lorem Foundation

Ryan Sowell

Director

Strand Therapeutics

Patrick Thiaville

VP

4basebio

Karina Thorn, PhD

Corporate VP and Head of Research, Global Nucleic Acid Therapies (GNAT)

Novo Nordisk

Jun Wang

Senior Machine Learning Scientist

Sanofi

Nathaniel Wang

CEO

Replicate Bioscience

Anna-Rose Welch

Editorial and Community Director Advancing RNA

Life Science Connect

Sally Werner

CEO

Cancer Support Community

Jim Weterings, PhD

VP, Head of Oligonucleotide Therapeutics

Bonito Biosciences

Renee Williams

Managing Partner

Williams Biotech Consulting, LLC

Weiyi Zhang

CEO & CSO

RiboX Therapeutics

John Zuris, PhD

Senior Director – Delivery and Editing Technologies

Editas Medicine